Pipeline growth, clinical development and manufacturing are all slated for a boost from a $474 million equity financing for Moderna Therapeutics Inc., a substantial follow-on to the messenger RNA (mRNA) specialist's monster $450 million series C round in January 2015 – a sum it has yet to even touch, CEO Stéphane Bancel told BioWorld Today.
